uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?
Show others and affiliations
2014 (English)In: Stem Cells, ISSN 1066-5099, E-ISSN 1549-4918, Vol. 32, no 9, 2430-2442 p.Article in journal (Refereed) Published
Abstract [en]

We have recently reported that therapeutic mesenchymal stromal cells (MSCs) have low engraftment and trigger the instant blood mediated inflammatory reaction (IBMIR) after systemic delivery to patients, resulting in compromised cell function. In order to optimize the product, we compared the immunomodulatory, blood regulatory, and therapeutic properties of freeze-thawed and freshly harvested cells. We found that freeze-thawed MSCs, as opposed to cells harvested from continuous cultures, have impaired immunomodulatory and blood regulatory properties. Freeze-thawed MSCs demonstrated reduced responsiveness to proinflammatory stimuli, an impaired production of anti-inflammatory mediators, increased triggering of the IBMIR, and a strong activation of the complement cascade compared to fresh cells. This resulted in twice the efficiency in lysis of thawed MSCs after 1 hour of serum exposure. We found a 50% and 80% reduction in viable cells with freshly detached as opposed to thawed in vitro cells, indicating a small benefit for fresh cells. In evaluation of clinical response, we report a trend that fresh cells, and cells of low passage, demonstrate improved clinical outcome. Patients treated with freshly harvested cells in low passage had a 100% response rate, twice the response rate of 50% observed in a comparable group of patients treated with freeze-thawed cells at higher passage. We conclude that cryobanked MSCs have reduced immunomodulatory and blood regulatory properties directly after thawing, resulting in faster complement-mediated elimination after blood exposure. These changes seem to be paired by differences in therapeutic efficacy in treatment of immune ailments after hematopoietic stem cell transplantation.

Place, publisher, year, edition, pages
2014. Vol. 32, no 9, 2430-2442 p.
Keyword [en]
Bone marrow stromal cells, Cellular therapy, Clinical translation, Cryopreservation, Immunotherapy, Engraftment, Instant blood-mediated inflammatory reaction
National Category
Cancer and Oncology Hematology Medical Biotechnology
Identifiers
URN: urn:nbn:se:uu:diva-233006DOI: 10.1002/stem.1729ISI: 000341294500013OAI: oai:DiVA.org:uu-233006DiVA: diva2:754523
Funder
Swedish Cancer Society, 11 0315Swedish Research Council, 6076170Vinnova, 2010-00501
Available from: 2014-10-10 Created: 2014-09-29 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Stenbeck-Funke, LillemorHamad, Osama A.Teramura, YujiNilsson-Ekdahl, KristinaNilsson, Bo

Search in DiVA

By author/editor
Stenbeck-Funke, LillemorHamad, Osama A.Teramura, YujiNilsson-Ekdahl, KristinaNilsson, Bo
By organisation
Clinical Immunology
In the same journal
Stem Cells
Cancer and OncologyHematologyMedical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 654 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf